Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comnprisinga metal, preferably radionuclide of rhenium or technetium;a hypoxia-localizing moiety; and,a complexing ligand, wherein said ligand and said radionuclide combined have cell membrane permeabilities greater than that of sucrose, are disclosed.

Abstract: Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

Abstract: Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

Abstract: Novel compounds of the formula ##STR1## where G.sup.1 and G.sup.2 are each independently --OH or --N(R.sup.2).sub.2, provided that at least one of G.sup.1 and G.sup.2 is --N(R.sup.2).sub.2, where each R.sup.2 is independently hydrogen, alkyl, aryl, acyl or --(A).sub.p --R.sup.a and the other variables are as defined in the specification and claims, and novel complexes of these compounds with metals are useful in diagnostic and therapeutic methods.

Abstract: Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

Abstract: Novel compounds of the formula ##STR1## where G.sup.1 and G.sup.2 are each independently --OH or --N(R.sup.2).sub.2, provided that at least one of G.sup.1 and G.sup.2 is --N(R.sup.2).sub.2, where each R.sup.2 is independently hydrogen, alkyl, aryl, acyl or --(A).sub.p --R.sup.a and the other variables are as defined in the specification and claims, and novel complexes of these compounds with metals are useful in diagnostic and therapeutic methods.

Abstract: Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

Abstract: New nonionic radiographic contrast agents having the formula ##STR1## wherein Y is a single bond, --CH.sub.2 CH.sub.2 --, --CH.sub.2 O--, --OCH.sub.2 --, ##STR2## --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.sub.2 --, --O-- or ##STR3## R.sub.1, R.sub.1 ' and R.sub.2 are the same or different and are hydrogen, alkyl or hydroxyalkyl.Hydroxyalkyl refers to such alkyl groups having 1 or more hydroxy groups. Preferred hydroxyalkyl groups include: ##STR4## R.sub.3 and R.sub.4 are the same or different and are hydrogen, methyl or --CH.sub.2 CH.sub.2 OH; R.sub.5 is hydrogen, alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH or OH and R.sub.6 is alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH, OH or hydrogen and may be the same or different than R.sub.5 and m is zero or one, with the proviso that no methylene or methine carbon atom of the heterocyclic ring is attached to both a nitrogen and an oxygen atom with the additional proviso that when Y is a single bond, m is not zero.

Abstract: Novel compounds containing a heteroatom-bearing bridge and novel complexes of these compounds with metals. The novel compounds and complexes are useful in diagnostic and therapeutic methods.

Abstract: New nonionic radiographic contrast agents having the formula ##STR1## wherein Y is a single bond, ##STR2## R.sub.1, R.sub.1 ' and R.sub.2 are the same or different and are hydrogen, alkyl or hydroxyalkyl.Hydroxyalkyl refers to such alkyl groups having 1 or more hydroxy groups. Preferred hydroxyalkyl groups include: ##STR3## R.sub.3 and R.sub.4 are the same or different and are hydrogen, methyl or --CH.sub.2 CH.sub.2 OH; R.sub.5 is hydrogen, alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH or OH and R.sub.6 is alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH, OH or hydrogen and may be the same or different than R.sub.5 and m is zero or one, with the proviso that no methylene or methine carbon atom of the heterocyclic ring is attached to both a nitrogen and an oxygen atom with the additional proviso that when Y is a single bond, m is not zero. These new contrast agents are water soluble and have desirable low osmolality and anticoagulant properties.

Abstract: Novel aromatic amide compounds comprising a ligand nucleus containing at least one aminocarboxylate, aminophosphonate and/or aminohydroxamate chelating group, substituted with a substituted aromatic amide group of the formula ##STR1## wherein R is ##STR2## or --[(CH.sub.2).sub.2 --Y]--R.sub.13, salts and/or multimers thereof, and metal chelates, particularly useful for MRI of the hepatobiliary system.